Johnson & Johnson: Schizophrenia trials

The registry lists 206 Schizophrenia studies with Johnson & Johnson as lead sponsor. 2 are open to participants now and 57 have results posted.

Early Phase 1 3Phase 1 40Phase 2 12Phase 3 74Phase 4 47No phase 31(a study in two phases counts in both)

Studies

Page 1 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With SchizophreniaRecruitingNCT07615426Phase 1
• Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum DisorderRecruitingNCT06229210Phase 3
• Lumateperone for the Prevention of Relapse in Patients With SchizophreniaCompletedNCT04959032Phase 3Results posted
• Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective DisorderCompletedNCT04779177Phase 1Results posted
• A Study of Paliperidone Palmitate 6-Month FormulationCompletedNCT04072575Phase 3Results posted
• A Study of Paliperidone Palmitate 6-Month FormulationCompletedNCT03345342Phase 3Results posted
• A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of TreatmentCompletedNCT02469155Phase 3Results posted
• A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass SpectrometryTerminatedNCT02462473Phase 2Results posted
• A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or SchizophreniformCompletedNCT02431702Phase 3Results posted
• A Trial to Assess the Antipsychotic Efficacy of ITI-007CompletedNCT02282761Phase 3Results posted
• An Observational Study to Evaluate Efficacy and Safety of Risperidone Long-Acting Injection for Treatment of SchizophreniaTerminatedNCT01894984Results posted
• An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective DisordersCompletedNCT01855074Phase 4Results posted
• Switching From Oral Antipsychotics to Long-Acting Risperidone in Participants With SchizophreniaCompletedNCT01726335Phase 4Results posted
• Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Patients With SchizophreniaCompletedNCT01724359Phase 4Results posted
• Safety, Efficacy and Tolerability Study of Paliperidone Extended-Release (ER) in Participants With SchizophreniaCompletedNCT01662648Phase 3Results posted
• An Efficacy Study of Paliperidone for the Prevention of Relapse in Participants With SchizophreniaCompletedNCT01662310Phase 3Results posted
• A Pharmacokinetic and Safety Study of Paliperidone Palmitate (JNS010) in Participants With SchizophreniaCompletedNCT01606254Phase 2Results posted
• A Trial to Explore the Tolerability, Safety and Efficacy of Paliperidone Extended Release in Patients With SchizophreniaCompletedNCT01606228Phase 3Results posted
• Symptomatic Remission and Social Function in Participants Treated With Paliperidone Extended Release (ER)CompletedNCT01577186Phase 4Results posted
• A Study to Evaluate Flexible Dose of Paliperidone Extended Release (ER) and Clinical Response in Participants With SchizophreniaCompletedNCT01577160Phase 4Results posted
• A Long-Term Study of JNS007ER in Patients With SchizophreniaCompletedNCT01561898Phase 3Results posted
• A Study of Flexibly Dosed Paliperidone Extended Release Tablets in Participants With SchizophreniaCompletedNCT01541371Phase 3Results posted
• A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With SchizophreniaCompletedNCT01529515Phase 3Results posted
• Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With SchizophreniaCompletedNCT01515423Phase 3Results posted
• Study of a Novel Antipsychotic ITI-007 in SchizophreniaCompletedNCT01499563Phase 2Results posted
• Safety and Efficacy Study of Paliperidone Extended Release (ER) Among Thai Schizophrenia ParticipantsCompletedNCT01387542Phase 4Results posted
• Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 YearsCompletedNCT01362439Phase 4Results posted
• An Efficacy and Safety Study of Paliperidone Palmitate in Participants With SchizophreniaCompletedNCT01299389Phase 3Results posted
• 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and IncarceratedCompletedNCT01157351Phase 4Results posted
• Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral AntipsychoticsCompletedNCT01081769Phase 3Results posted
• A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in ChildrenCompletedNCT01050582Phase 4Results posted
• A Study to Evaluate Participants Satisfaction, Quality of Life and Effectiveness of Flexible-Dose of Paliperidone Extended Release (ER) in Participants With Schizophrenia, Previously Treated With RisperidoneCompletedNCT01010776Phase 4Results posted
• An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With SchizophreniaCompletedNCT01009047Phase 3Results posted
• An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective DisorderCompletedNCT00992407Phase 4Results posted
• 28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 YearsTerminatedNCT00946985Phase 4Results posted
• A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patients and Healthy ControlsTerminatedNCT00934635Phase 4Results posted
• Efficacy Study of Paliperidone to Evaluate Subjective Change in Well-being and Drug Attitude in Schizophrenic ParticipantsCompletedNCT00784238Phase 4Results posted
• Phase 4 Study to Evaluate Efficacy of Paliperidone Extended-Release(ER) in Schizophrenic ParticipantsCompletedNCT00761605Phase 4Results posted
• Paliperidone Extended Release(ER) Effectiveness Study to Evaluate the Objective Symptom Change and Symptomatic RemissionCompletedNCT00761579Phase 4Results posted
• PaliperidoNe Extended-Release [ER] Dosing and Clinical Response in Acute SchizophreniaCompletedNCT00761189Phase 4Results posted
• An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended-Release (ER) in Participants With SchizophreniaCompletedNCT00757705Phase 4Results posted
• A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With SchizophreniaCompletedNCT00645099Phase 3Results posted
• A Comparative Study of Paliperidone Palmitate and Risperidone Long Acting Injection (LAI) in Participants With SchizophreniaCompletedNCT00604279Phase 3Results posted
• Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With SchizophreniaCompletedNCT00590577Phase 3Results posted
• Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With SchizophreniaCompletedNCT00589914Phase 3Results posted
• An Efficacy and Safety Study of Paliperidone Extended-Release (ER) Tablets in Participants With SchizophreniaCompletedNCT00566631Phase 3Results posted
• Study to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver DiseaseCompletedNCT00535145Phase 4Results posted
• Study to Measure Drug Satisfaction of Patients With Schizophrenia After Switching From Risperidone to PaliperidoneCompletedNCT00535132Phase 4Results posted
• An Efficacy and Safety Study of One Dosage of Paliperidone Extended Release (ER) in Treating Patients With SchizophreniaCompletedNCT00524043Phase 4Results posted
• A Double-blind, Placebo-controlled Study of the Safety and Efficacy of Paliperidone Extended Release (ER) in the Treatment of Schizophrenia in Adolescent PatientsCompletedNCT00518323Phase 3Results posted
• Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.CompletedNCT00488319Phase 3Results posted
• An Open Label Multicentre Study to Determine the Dose Distribution of Paliperidone ER in Patients With SchizophreniaCompletedNCT00473434Phase 3Results posted
• A Study to Evaluate Effectiveness and Safety of ER OROS Paliperidone in Patients With SchizophreniaCompletedNCT00396565Phase 3Results posted
• Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With SchizophreniaCompletedNCT00299702Phase 4Results posted
• An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With SchizophreniaCompletedNCT00269919Phase 4Results posted
• A Study of Risperidone Long-Acting Injection Versus Oral Antipsychotics in Schizophrenia Participants With a History of Being Poorly Compliant With Taking Their MedicationTerminatedNCT00256997Phase 4Results posted
• A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early PsychosisCompletedNCT00246259Phase 4Results posted
• Long-acting Injectable Risperidone in Patients With Schizophrenia After an Acute EpisodeCompletedNCT00216671Phase 4Results posted
• A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective DisorderCompletedNCT00216476Phase 3Results posted
• Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective DisorderCompletedNCT06627413Phase 1
• A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare SettingsCompletedNCT04940039Phase 4
• Pharmacokinetics, Safety, and Tolerability of Lumateperone Long-Acting Injectable in Patients With SchizophreniaCompletedNCT04709224Phase 1
• A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthlyCompletedNCT03809325
• A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare FacilitiesCompletedNCT03713658Phase 4
• A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in PortugalCompletedNCT03666715
• A Study for Schizophrenia Relapse PredictionCompletedNCT03629951
• Sustainable Early Episode Clinic Study (SEEC)CompletedNCT03571685Not applicable
• Evaluation of the Functional Remission Occurrence and Predictive Factors in SchizophreniaCompletedNCT02874560
• A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month FormulationCompletedNCT02713282Phase 3
• A Study to Assess the Rate of Hospitalization in Participants With Schizophrenia Treated With AntipsychoticsCompletedNCT02712463
• Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)CompletedNCT02600741
• Non-Interventional Study of Participants With Newly Diagnosed Schizophrenia Treated With Paliperidone PalmitateCompletedNCT02532842
• Receptor Occupancy of ITI-007 Using Positron Emission Tomography (PET) in Patients With Stable SchizophreniaCompletedNCT02288845Phase 2
• Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric ParticipantsCompletedNCT02087579Phase 1
• A Safety and Effectiveness Study of Paliperidone Palmitate in Chinese Patients With SchizophreniaCompletedNCT01947803Phase 4
• A Clinical Pharmacology Study of JNS010 (Paliperidone Palmitate) in Patients With SchizophreniaCompletedNCT01942382Phase 1
• A Study of Usage of Paliperidone Palmitate in Patients With Schizophrenia in a Hospital SettingCompletedNCT01926912
• Maintenance of Efficacy With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective DisorderCompletedNCT01888107Phase 3
• A Study to Observe the Safety and Tolerability of Paliperidone Palmitate (Invega Sustenna) in Korean Schizophrenic PatientsCompletedNCT01819818
• A Pharmacokinetics Study to Evaluate Safety and Tolerability of JNJ-37822681 in Participants With Stable SchizophreniaCompletedNCT01812642Phase 2
• A Study to Assess Learning Performance in Patients With Schizophrenia and Young and Elderly Healthy VolunteersCompletedNCT01788436Early Phase 1
• A Study of Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral AntipsychoticsCompletedNCT01685931Phase 4
• A Comparative Study to Evaluate the Evolution of Medication Satisfaction and Adherence in Patients Unsatisfied With Current Oral Atypical Antipsychotics by Switching Medication to Paliperidone PalmitateCompletedNCT01682161Phase 4
• A Study to Evaluate the Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Cognitive Function in Clinically Stable Patients With SchizophreniaTerminatedNCT01670071Phase 4
• A Comparative Study of Patient Satisfaction Between Continued Administration of Previous Antipsychotics Versus Switched Administration to Paliperidone ER in Non-satisfied Patients With Previous Antipsychotic DrugTerminatedNCT01592201Phase 4
• A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Paliperidone Palmitate in Patients With SchizophreniaCompletedNCT01559272Phase 1
• A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Subjects With Acute SchizophreniaCompletedNCT01527305Phase 4
• Treatment of Patients With Recently Exacerbated Schizophrenia With Paliperidone PalmitateCompletedNCT01448720Phase 3
• FYS Study: Epidemiological, Multicentre, Cross-sectional Study in a Clinical Practice Environment, About the Relationship Between Functioning Status and the Quality of Sleep Perceived by Schizophrenic Outpatients in SpainCompletedNCT01376492
• Paliperidone Palmitate Effectiveness Assessment Registry - Longitudinal (PEARL)CompletedNCT01362426
• Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With SchizophreniaCompletedNCT01323205Phase 2
• An Epidemiological Study to Assess the Psychosocial and Symptomatic Remission and Community Integration Status in Patients With SchizophreniaCompletedNCT01309373
• Paliperidone Palmitate Flexible Dosing in SchizophreniaCompletedNCT01281527Phase 3
• A Study of Paliperidone Palmitate in Japanese Patients With SchizophreniaCompletedNCT01258920Phase 3
• Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric HospitalWithdrawnNCT01193166Phase 4
• The Effect of Nicotine on Arousal, Cognition and Social Cognition in Schizophrenic PatientsCompletedNCT01186471Early Phase 1
• Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health OrganizationsCompletedNCT01181960
• The Effect of Nicotine on Arousal, Cognition and Social Cognition in Young and Elderly Healthy Subjects.CompletedNCT01181934Early Phase 1
• The Effect of Ketamine on AttentivenessCompletedNCT01165294Phase 1
• A Safety and Pharmacokinetic Study of Paliperidone Palmitate in Patients With SchizophreniaCompletedNCT01150448Phase 1